45 related articles for article (PubMed ID: 16023001)
21. Altered cellular kinetics in the growth plate of the femoral head of spontaneously hypertensive rats.
Park H; Kong SY; Kim HW
Yonsei Med J; 2012 May; 53(3):625-33. PubMed ID: 22477009
[TBL] [Abstract][Full Text] [Related]
22. Evidence for using bisphosphonate to treat Legg-Calvé-Perthes disease.
Young ML; Little DG; Kim HK
Clin Orthop Relat Res; 2012 Sep; 470(9):2462-75. PubMed ID: 22270467
[TBL] [Abstract][Full Text] [Related]
23. Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.
Brouwers JE; Lambers FM; Gasser JA; van Rietbergen B; Huiskes R
Calcif Tissue Int; 2008 Mar; 82(3):202-11. PubMed ID: 18286219
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
Russell RG; Watts NB; Ebetino FH; Rogers MJ
Osteoporos Int; 2008 Jun; 19(6):733-59. PubMed ID: 18214569
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of avascular bone necrosis of the knee with neridronate: a case report.
Corrado A; Quarta L; Errico S; Cantatore FP
Rheumatol Int; 2007 Jul; 27(9):891-3. PubMed ID: 17285278
[No Abstract] [Full Text] [Related]
26. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.
Thakkar SG; Isada C; Smith J; Karam MA; Reed J; Tomford JW; Englund K; Richmond M; Licata A; Hatch C; Hussein MA
Med Oncol; 2006; 23(1):51-6. PubMed ID: 16645229
[TBL] [Abstract][Full Text] [Related]
27. Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in man and experimental animals.
Boss JH; Misselevich I
Vet Pathol; 2003 Jul; 40(4):345-54. PubMed ID: 12824505
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats.
Little DG; Peat RA; Mcevoy A; Williams PR; Smith EJ; Baldock PA
J Bone Miner Res; 2003 Nov; 18(11):2016-22. PubMed ID: 14606515
[TBL] [Abstract][Full Text] [Related]
29. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
[TBL] [Abstract][Full Text] [Related]
30. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis.
Kim HK; Morgan-Bagley S; Kostenuik P
J Bone Miner Res; 2006 Dec; 21(12):1946-54. PubMed ID: 17002576
[TBL] [Abstract][Full Text] [Related]
31. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.
Amanat N; McDonald M; Godfrey C; Bilston L; Little D
J Bone Miner Res; 2007 Jun; 22(6):867-76. PubMed ID: 17371160
[TBL] [Abstract][Full Text] [Related]
32. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.
Little DG; McDonald M; Bransford R; Godfrey CB; Amanat N
J Bone Miner Res; 2005 Nov; 20(11):2044-52. PubMed ID: 16234978
[TBL] [Abstract][Full Text] [Related]
33. Zoledronic acid improves femoral head sphericity in a rat model of perthes disease.
Little DG; McDonald M; Sharpe IT; Peat R; Williams P; McEvoy T
J Orthop Res; 2005 Jul; 23(4):862-8. PubMed ID: 16023001
[TBL] [Abstract][Full Text] [Related]
34. Potential for bisphosphonate treatment in Legg-Calve-Perthes disease.
Little DG; Kim HK
J Pediatr Orthop; 2011 Sep; 31(2 Suppl):S182-8. PubMed ID: 21857436
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
